Not sure what you're reading. I'm majorly enthusiastic about Kevetrin. The comps I posted show that the upfront payments for a partnership on Kevetrin would be 4-10x of our market cap on just our preclinical and phase 1 data alone. There is no need to even debate the phase 2 results as it is not needed to secure hundreds of millions upfront. Any of those deals would send us to $2+ over night. If you think those comps are undervalued, well more power to you, I hope you're right.

I thought the phase 2 results were very promising and look forward to repeating the results with a pill.